Yazar "Batgi, Hikmetullah" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Stem cell mobilization kinetics in elderly patients with multiple myeloma
    (Pergamon-Elsevier Science Ltd, 2018) Dogu, Mehmet Hilmi; Batgi, Hikmetullah; Erkurt, Mehmet Ali; Hacioglu, Sibel; Tekgunduz, Emre; Kaya, Emin; Iskender, Dicle
    In this study, we aimed to investigate whether the procedure and product kinetics differ according to age groups in advanced-age MM patients who underwent autologous HSCT. 59 patients who underwent autologous HSCT were retrospectively analyzed. Then, the patients were divided into two groups as 60-65 years and >= 65 years. It was significantly lower in >= 65 years group (p=0.008) and proportionally, the procedure duration was also significantly shortened in this group (p=0.013). Total number of collected CD34 positive stem cells was 6.20 x 106 (+/- 3.83) in 60-65 years group while it was 5.51 x 106 (+/- 2.48) in >= 65 years group with no statistically significant difference. (p=0.825). In conclusion, there was no significant difference in terms of the number of collected CD34-positive stem cells in this study that investigates the mobilization data, procedure and product kinetics, we think that successful stem cell mobilization can be performed in appropriately selected patients regardless of age. (C) 2018 Elsevier Ltd. All rights reserved.
  • Küçük Resim
    Öğe
    Stem cell mobilization kinetics in elderly patients with multiple myeloma
    (Pergamon-elsevıer scıence ltd, the boulevard, langford lane, kıdlıngton, oxford ox5 1gb, england, 2018) Dogu, Mehmet Hilmi; Batgi, Hikmetullah; Erkurt, Mehmet Ali; Hacioglu, Sibel
    In this study, we aimed to investigate whether the procedure and product kinetics differ according to age groups in advanced-age MM patients who underwent autologous HSCT. 59 patients who underwent autologous HSCT were retrospectively analyzed. Then, the patients were divided into two groups as 60-65 years and >= 65 years. It was significantly lower in >= 65 years group (p=0.008) and proportionally, the procedure duration was also significantly shortened in this group (p=0.013). Total number of collected CD34 positive stem cells was 6.20 x 106 (+/- 3.83) in 60-65 years group while it was 5.51 x 106 (+/- 2.48) in >= 65 years group with no statistically significant difference. (p=0.825). In conclusion, there was no significant difference in terms of the number of collected CD34-positive stem cells in this study that investigates the mobilization data, procedure and product kinetics, we think that successful stem cell mobilization can be performed in appropriately selected patients regardless of age. (C) 2018 Elsevier Ltd. All rights reserved.
  • Küçük Resim Yok
    Öğe
    The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantation
    (Pergamon-Elsevier Science Ltd, 2025) Batgi, Hikmetullah; Zorlu, Tugba; Erkurt, Mehmet Ali; Uzay, Ant; Hindilerden, Ipek Yonal; Pepeler, Mehmet Sezgin; Apaydin, Merve
    Background and objectives: Acute leukemia patients who relapse after the first allogeneic stem-cell transplantation (HSCT1) have a poor prognosis. Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) relapsing after HSCT1. Our aim is to evaluate the efficacy of HSCT2 in acute leukemia patients who relapsed after HSCT1. Material and methods: In the current study, we retrospectively analyzed the data of 72 patients who underwent HSCT2. Forty-six patients with AML and 26 patients with ALL were included in the study. Results: Before undergoing HSCT2, 47 % of patients were in complete remission. Median follow-up was 8 (1-109) months. Mortality at last follow-up was 61.1 %, and the median overall survival was 11 months (95 % CI: 1-22.9). Univariate analysis identified that age, Eastern Cooperative Oncology Group (ECOG), Body Mass Index, chimerism, conditioning regimen, CD34+ infused cell count, post-transplant cyclophosphamide usage, disease type, pre transplant hemoglobin-lymphocyte-lactate dehydrogenase-ferritin might be significant factors. After multivariate analysis ECOG (HR: 2.142; 95 % CI: 1.061-4.326; p = 0.034) was the only independent predictor for survival. Conclusion: HSCT2 remains a feasible but high-risk treatment option for patients with relapsed acute leukemia after HSCT1. Our findings confirm that ECOG performance status is a key determinant of survival despite advances in transplantation techniques.